<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02737332</url>
  </required_header>
  <id_info>
    <org_study_id>CHL-AA-201</org_study_id>
    <nct_id>NCT02737332</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
  <acronym>STAAR</acronym>
  <official_title>A Randomized, Open-Label, Active-Controlled, Multi-Center Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer: The STAAR STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharmaceutical Industries Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharmaceutical Industries Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the serum testosterone levels in patients with&#xD;
      Metastatic Castration-Resistant Prostate Cancer on SoluMatrix™ Abiraterone Acetate as&#xD;
      Compared to Abiraterone Acetate&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a 12-week, open-label study of abiraterone acetate in at least 50 patients with&#xD;
      metastatic castration-resistant prostate cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 21, 2016</start_date>
  <completion_date type="Actual">February 27, 2017</completion_date>
  <primary_completion_date type="Actual">February 27, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Testosterone Levels</measure>
    <time_frame>Average of Day 9 and 10</time_frame>
    <description>Blood Sample tested for Serum Testosterone Levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA Levels</measure>
    <time_frame>Day 28, Day 56, and Day 84</time_frame>
    <description>All patients randomized to one of the two treatment groups, round about level of PSA.&#xD;
These were assessed only at the said Outcome Measure Time Frame. No additional time points to the said endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects With PSA-50 Response</measure>
    <time_frame>Day 28, Day 56, and Day 84</time_frame>
    <description>Proportion of patients with complete suppression of PSA-50 were reported by treatment and compared for between-group differences.&#xD;
These were assessed only at the said Outcome Measure Time Frame. No additional time points to the said endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Testosterone Levels</measure>
    <time_frame>Day 28, Day 56, and Day 84</time_frame>
    <description>These were assessed only at the said Outcome Measure Time Frame. No additional time points to the said endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady State Trough Concentration of Arbiraterone</measure>
    <time_frame>Day 09, Day 28, Day 56, and Day 84</time_frame>
    <description>These were assessed only at the said Outcome Measure Time Frame. No additional time points to the said endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-inf)</measure>
    <time_frame>60 to 30 minutes prior to dosing and over 24 Hours post-dose</time_frame>
    <description>Steady state systemic exposure parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-24 hr)</measure>
    <time_frame>60 to 30 minutes prior to dosing and over 24 Hours post-dose</time_frame>
    <description>Blood samples for pre-dose PK profiling were to be collected approximately 45 minutes before dosing, i.e., within 60 to 30 minutes prior to dosing. Post-dose blood samples were to be collected throughout the day at the times (15 mins, 30 mins, 1 hr, 1.5 hr, 2.0 hr 3 hr, 4 hr, 6 hr, 8 hr, 9 hr, 24 hr).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-t)</measure>
    <time_frame>60 to 30 minutes prior to dosing and over 24 Hours post-dose</time_frame>
    <description>Blood samples for pre-dose PK profiling were to be collected approximately 45 minutes before dosing, i.e., within 60 to 30 minutes prior to dosing. Post-dose blood samples were to be collected throughout the day at the times (15 mins, 30 mins, 1 hr, 1.5 hr, 2.0 hr 3 hr, 4 hr, 6 hr, 8 hr, 9 hr, 24 hr).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>60 to 30 minutes prior to dosing and over 24 Hours post-dose</time_frame>
    <description>Blood samples for pre-dose PK profiling were to be collected approximately 45 minutes before dosing, i.e., within 60 to 30 minutes prior to dosing. Post-dose blood samples were to be collected throughout the day at the times (15 mins, 30 mins, 1 hr, 1.5 hr, 2.0 hr 3 hr, 4 hr, 6 hr, 8 hr, 9 hr, 24 hr).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Zytiga® (Abiraterone Acetate)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1,000 MG (4 x 250 mg qd)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SoluMatrix™ (Abiraterone Acetate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg (4 x 125 mg qd)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zytiga® (Abiraterone Acetate)</intervention_name>
    <description>Zytiga® 1,000 mg (4 x 250 mg qd) tablets plus one 5 mg prednisone tablet to be taken bid, spaced approximately 12 hours apart</description>
    <arm_group_label>Zytiga® (Abiraterone Acetate)</arm_group_label>
    <other_name>Zytiga®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SoluMatrix™ (Abiraterone Acetate)</intervention_name>
    <description>SoluMatrix™ 500 mg (4 x 125 mg qd) tablets plus one 4 mg methylprednisolone tablet bid, spaced approximately 12 hours apart</description>
    <arm_group_label>SoluMatrix™ (Abiraterone Acetate)</arm_group_label>
    <other_name>SoluMatrix™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent obtained prior to any study-related procedure being performed&#xD;
&#xD;
          2. Male subjects at least 18 years of age or older at time of consent&#xD;
&#xD;
          3. Pathologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          4. Ongoing therapy with a GnRH agonist or antagonist AND serum testosterone level &lt;50&#xD;
             ng/dL at screening&#xD;
&#xD;
          5. Metastatic disease documented by computed tomography (CT)/ magnetic resonance imaging&#xD;
             (MRI) or bone scan. Imaging obtained within 42 days prior to the start of study&#xD;
             medication will be accepted.&#xD;
&#xD;
          6. Meeting disease progression according to the recommendations of the prostate cancer&#xD;
             working group 2 by one of the following criteria:&#xD;
&#xD;
               -  Two rises of PSA (taken a minimum of 1 week apart) from a baseline measurement of&#xD;
                  at least 2 ng/mL,&#xD;
&#xD;
               -  Imaging progression (CT/MRI) by RECIST criteria&#xD;
&#xD;
               -  Nuclear scan progression by new lesion.&#xD;
&#xD;
          7. Discontinuation of flutamide or nilutamide, and other anti-androgens at least 4 weeks&#xD;
             prior to the start of study medication; discontinuation of bicalutamide at least 6&#xD;
             weeks prior to start of study medication.&#xD;
&#xD;
          8. Discontinuation of Radiotherapy &gt; 4 weeks prior to start of study medication.&#xD;
&#xD;
          9. ECOG performance status of 0-1 at screening&#xD;
&#xD;
         10. Screening blood counts of the following:&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 1500/µL&#xD;
&#xD;
               -  Platelets &gt; 100,000/µL&#xD;
&#xD;
               -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
         11. Screening chemistry values of the following:&#xD;
&#xD;
               -  ALT and AST &lt; 2.5 x ULN&#xD;
&#xD;
               -  Total bilirubin &lt; 1.5 x ULN&#xD;
&#xD;
               -  Creatinine&lt; 1.5 x ULN&#xD;
&#xD;
               -  Albumin &gt; 3.0 g/dL&#xD;
&#xD;
         12. Potassium &gt; 3.5 mmol/L&#xD;
&#xD;
         13. Life expectancy of at least 6 months at screening&#xD;
&#xD;
         14. Subject is willing and able to comply with all protocol requirements assessments&#xD;
&#xD;
         15. Agrees to protocol-defined use of effective contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of impaired pituitary or adrenal gland function&#xD;
&#xD;
          2. Prior therapy with abiraterone acetate, orteronel, ketoconazole or any other CYP17&#xD;
             inhibitor&#xD;
&#xD;
          3. Prior therapy with enzalutamide&#xD;
&#xD;
          4. Prior use of experimental androgen receptor antagonist&#xD;
&#xD;
          5. Previous exposure to Ra-223:Xofigo&#xD;
&#xD;
          6. Previous chemotherapy&#xD;
&#xD;
          7. Initiation of bisphosphonate or denosumab therapy within 30 days prior to the start of&#xD;
             study medication. Patients who are on a stable dose of these medications for at least&#xD;
             30 days at the time of starting study drug are eligible.&#xD;
&#xD;
          8. Therapy with estrogen within 30 days prior to the start of study medication&#xD;
&#xD;
          9. Use of systemic glucocorticoids equivalent to &gt; 10 mg of prednisone daily; patients&#xD;
             who have discontinued or have reduced dose to &lt; 10 mg prednisone within 14 days prior&#xD;
             to the start of study medication will be eligible&#xD;
&#xD;
         10. Prior use of any herbal products that may decrease PSA levels (eg., saw palmetto)&#xD;
             within 30 days of start of study medication&#xD;
&#xD;
         11. Known metastases to the brain or CNS involvement&#xD;
&#xD;
         12. History of other malignancy within the previous 2 years&#xD;
&#xD;
         13. Major surgery within 30 days prior to the start of study medication&#xD;
&#xD;
         14. Blood transfusion within 30 days of screening&#xD;
&#xD;
         15. Serious, persistent infection within 14 days of the start of study medication&#xD;
&#xD;
         16. Persistent pain that requires the use of a narcotic analgesic&#xD;
&#xD;
         17. Known gastrointestinal disease or condition that may impair absorption&#xD;
&#xD;
         18. Treatment with any investigational drug within 4 weeks prior to Day -1 of the study.&#xD;
&#xD;
         19. Known history of human immunodeficiency virus (HIV) or seropositive test for hepatitis&#xD;
             C virus or hepatitis B virus&#xD;
&#xD;
         20. Have poorly controlled diabetes.&#xD;
&#xD;
         21. Uncontrolled hypertension&#xD;
&#xD;
         22. History of New York Heart Association (NYHA) class III or IV heart failure&#xD;
&#xD;
         23. Serious concurrent illness, including psychiatric illness, that would interfere with&#xD;
             study participation&#xD;
&#xD;
         24. Inability to swallow tablets whole&#xD;
&#xD;
         25. Known hypersensitivity to any excipients in study medications&#xD;
&#xD;
         26. Moderate to severe hepatic impairment (Child-Pugh Classes B and C)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Nemeth, PhD</last_name>
    <role>Study Director</role>
  </overall_official>
  <location>
    <facility>
      <name>Alliance Research</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tower Urology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Bernardino Urological</name>
      <address>
        <city>San Bernardino</city>
        <state>California</state>
        <zip>92404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skyline Urology</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research Institute</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates, P.C.</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manatee Medical Research</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Idaho Urology</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Iowa Clinic</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wichita Urology Group</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lincoln Urology, PC</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooklyn Urology Research Group</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Urologist of North Carolina</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Clinics of North Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 25, 2016</study_first_submitted>
  <study_first_submitted_qc>April 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2016</study_first_posted>
  <results_first_submitted>May 2, 2019</results_first_submitted>
  <results_first_submitted_qc>July 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 12, 2020</results_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 10, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT02737332/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Zytiga® (Abiraterone Acetate)</title>
          <description>Zytiga® 1,000 mg (4 x 250 mg qd) tablets</description>
        </group>
        <group group_id="P2">
          <title>SoluMatrix™ (Abiraterone Acetate)</title>
          <description>SoluMatrix™ 500 mg (4 x 125 mg qd) tablets</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zytiga® (Abiraterone Acetate)</title>
          <description>Zytiga® 1,000 mg (4 x 250 mg qd) tablets</description>
        </group>
        <group group_id="B2">
          <title>SoluMatrix™ (Abiraterone Acetate)</title>
          <description>SoluMatrix™ 500 mg (4 x 125 mg qd) tablets</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.5" spread="9.4"/>
                    <measurement group_id="B2" value="77" spread="8.9"/>
                    <measurement group_id="B3" value="75.1" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Testosterone Levels</title>
        <description>Blood Sample tested for Serum Testosterone Levels</description>
        <time_frame>Average of Day 9 and 10</time_frame>
        <population>Analysis of serum T levels in the ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Zytiga® (Abiraterone Acetate)</title>
            <description>Zytiga® 1,000 mg (4 x 250 mg qd) tablets</description>
          </group>
          <group group_id="O2">
            <title>SoluMatrix™ (Abiraterone Acetate)</title>
            <description>SoluMatrix™ 500 mg (4 x 125 mg qd) tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Testosterone Levels</title>
          <description>Blood Sample tested for Serum Testosterone Levels</description>
          <population>Analysis of serum T levels in the ITT population</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="0.03"/>
                    <measurement group_id="O2" value="1.05" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The bioequivalence between the two products was concluded if the 90% CIs (based on log transformed data and anti-logged) for the ratio of the geometric means lie completely within the range 80%-125%.</non_inferiority_desc>
            <p_value>0.4879</p_value>
            <p_value_desc>One-way ANOVA model with treatment as the independent variable, and the least-square means and standard error of Testosterone levels under each treatment and the between-treatment difference in LS means was reported.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio of treatments</param_type>
            <param_value>1.019</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.964</ci_lower_limit>
            <ci_upper_limit>1.077</ci_upper_limit>
            <estimate_desc>Geometric mean ratio of experimental and reference product was determined by exponentiating least-squares means of log-transformed value.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PSA Levels</title>
        <description>All patients randomized to one of the two treatment groups, round about level of PSA.&#xD;
These were assessed only at the said Outcome Measure Time Frame. No additional time points to the said endpoint</description>
        <time_frame>Day 28, Day 56, and Day 84</time_frame>
        <population>ITT population:The intention-to-treat (ITT) population is defined as all subjects who are randomized to one of the two treatment groups. The ITT population is the primary population for PD evaluation. The ITT population will be identified and finalized before the database is locked.</population>
        <group_list>
          <group group_id="O1">
            <title>Zytiga® (Abiraterone Acetate)</title>
            <description>Zytiga® 1,000 mg (4 x 250 mg qd) tablets</description>
          </group>
          <group group_id="O2">
            <title>SoluMatrix™ (Abiraterone Acetate)</title>
            <description>SoluMatrix™ 500 mg (4 x 125 mg qd) tablets</description>
          </group>
        </group_list>
        <measure>
          <title>PSA Levels</title>
          <description>All patients randomized to one of the two treatment groups, round about level of PSA.&#xD;
These were assessed only at the said Outcome Measure Time Frame. No additional time points to the said endpoint</description>
          <population>ITT population:The intention-to-treat (ITT) population is defined as all subjects who are randomized to one of the two treatment groups. The ITT population is the primary population for PD evaluation. The ITT population will be identified and finalized before the database is locked.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" spread="11.33"/>
                    <measurement group_id="O2" value="22.37" spread="12.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.84" spread="12.58"/>
                    <measurement group_id="O2" value="25.29" spread="13.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.88" spread="13.43"/>
                    <measurement group_id="O2" value="26.46" spread="15.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The bioequivalence between the two products was concluded if the 90% CIs (based on log transformed data and anti-logged) for the ratio of the geometric means lie completely within the range 80%-125%.</non_inferiority_desc>
            <p_value>0.3642</p_value>
            <p_value_desc>One-way ANOVA model with treatment as the independent variable, and the least-square means and standard error of Testosterone levels under each treatment and the between-treatment difference in LS means was reported.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.994</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0451</ci_lower_limit>
            <ci_upper_limit>2.192</ci_upper_limit>
            <estimate_desc>Geometric mean ratio of experimental and reference product was determined by exponentiating least-squares means of log-transformed value.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The bioequivalence between the two products was concluded if the 90% CIs (based on log transformed data and anti-logged) for the ratio of the geometric means lie completely within the range 80%-125%.</non_inferiority_desc>
            <p_value>0.4069</p_value>
            <p_value_desc>One-way ANOVA model with treatment as the independent variable, and the least-square means and standard error of Testosterone levels under each treatment and the between-treatment difference in LS means was reported.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.810</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.338</ci_lower_limit>
            <ci_upper_limit>1.939</ci_upper_limit>
            <estimate_desc>Geometric mean ratio of experimental and reference product was determined by exponentiating least-squares means of log-transformed value.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>One-way ANOVA model with treatment as the independent variable, and the least-square means and standard error of Testosterone levels under each treatment and the between-treatment difference in LS means was reported.</non_inferiority_desc>
            <p_value>0.7186</p_value>
            <p_value_desc>The bioequivalence between the two products was concluded if the 90% CIs (based on log transformed data and anti-logged) for the ratio of the geometric means lie completely within the range 80%-125%.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>1.039</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.412</ci_lower_limit>
            <ci_upper_limit>2.617</ci_upper_limit>
            <estimate_desc>Geometric mean ratio of experimental and reference product was determined by exponentiating least-squares means of log-transformed value.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects With PSA-50 Response</title>
        <description>Proportion of patients with complete suppression of PSA-50 were reported by treatment and compared for between-group differences.&#xD;
These were assessed only at the said Outcome Measure Time Frame. No additional time points to the said endpoint.</description>
        <time_frame>Day 28, Day 56, and Day 84</time_frame>
        <population>ITT population:The intention-to-treat (ITT) population is defined as all subjects who are randomized to one of the two treatment groups. The ITT population is the primary population for PD evaluation. The ITT population will be identified and finalized before the database is locked.</population>
        <group_list>
          <group group_id="O1">
            <title>Zytiga® (Abiraterone Acetate)</title>
            <description>Zytiga® 1,000 mg (4 x 250 mg qd) tablets</description>
          </group>
          <group group_id="O2">
            <title>SoluMatrix™ (Abiraterone Acetate)</title>
            <description>SoluMatrix™ 500 mg (4 x 125 mg qd) tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects With PSA-50 Response</title>
          <description>Proportion of patients with complete suppression of PSA-50 were reported by treatment and compared for between-group differences.&#xD;
These were assessed only at the said Outcome Measure Time Frame. No additional time points to the said endpoint.</description>
          <population>ITT population:The intention-to-treat (ITT) population is defined as all subjects who are randomized to one of the two treatment groups. The ITT population is the primary population for PD evaluation. The ITT population will be identified and finalized before the database is locked.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.4"/>
                    <measurement group_id="O2" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.4"/>
                    <measurement group_id="O2" value="63.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0"/>
                    <measurement group_id="O2" value="68.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Testosterone Levels</title>
        <description>These were assessed only at the said Outcome Measure Time Frame. No additional time points to the said endpoint.</description>
        <time_frame>Day 28, Day 56, and Day 84</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zytiga® (Abiraterone Acetate)</title>
            <description>Zytiga® 1,000 mg (4 x 250 mg qd) tablets</description>
          </group>
          <group group_id="O2">
            <title>SoluMatrix™ (Abiraterone Acetate)</title>
            <description>SoluMatrix™ 500 mg (4 x 125 mg qd) tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Testosterone Levels</title>
          <description>These were assessed only at the said Outcome Measure Time Frame. No additional time points to the said endpoint.</description>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="0.01"/>
                    <measurement group_id="O2" value="1.01" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="1.03"/>
                    <measurement group_id="O2" value="2.56" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0"/>
                    <measurement group_id="O2" value="1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The bioequivalence between the two products was concluded if the 90% CIs (based on log transformed data and anti-logged) for the ratio of the geometric means lie completely within the range 80%-125%.</non_inferiority_desc>
            <p_value>0.9211</p_value>
            <p_value_desc>One-way ANOVA model with treatment as the independent variable, and the least-square means and standard error of Testosterone levels under each treatment and the between-treatment difference in LS means was reported.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.999</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.980</ci_lower_limit>
            <ci_upper_limit>1.018</ci_upper_limit>
            <estimate_desc>Geometric mean ratio of experimental and reference product was determined by exponentiating least-squares means of log-transformed value.</estimate_desc>
            <other_analysis_desc>ANOVA-model-based Least-Square Mean</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The bioequivalence between the two products was concluded if the 90% CIs (based on log transformed data and anti-logged) for the ratio of the geometric means lie completely within the range 80%-125%.</non_inferiority_desc>
            <p_value>0.3037</p_value>
            <p_value_desc>One-way ANOVA model with treatment as the independent variable, and the least-square means and standard error of Testosterone levels under each treatment and the between-treatment difference in LS means was reported.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>1.168</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.900</ci_lower_limit>
            <ci_upper_limit>1.515</ci_upper_limit>
            <estimate_desc>Geometric mean ratio of experimental and reference product was determined by exponentiating least-squares means of log-transformed value.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The bioequivalence between the two products was concluded if the 90% CIs (based on log transformed data and anti-logged) for the ratio of the geometric means lie completely within the range 80%-125%.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>1.000</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.000</ci_lower_limit>
            <ci_upper_limit>1.000</ci_upper_limit>
            <estimate_desc>Geometric mean ratio of experimental and reference product was determined by exponentiating least-squares means of log-transformed value.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steady State Trough Concentration of Arbiraterone</title>
        <description>These were assessed only at the said Outcome Measure Time Frame. No additional time points to the said endpoint.</description>
        <time_frame>Day 09, Day 28, Day 56, and Day 84</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Zytiga® (Abiraterone Acetate)</title>
            <description>Zytiga® 1,000 mg (4 x 250 mg qd) tablets</description>
          </group>
          <group group_id="O2">
            <title>SoluMatrix™ (Abiraterone Acetate)</title>
            <description>SoluMatrix™ 500 mg (4 x 125 mg qd) tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Steady State Trough Concentration of Arbiraterone</title>
          <description>These were assessed only at the said Outcome Measure Time Frame. No additional time points to the said endpoint.</description>
          <population>Safety Population</population>
          <units>ng/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 09</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.938" spread="7.044"/>
                    <measurement group_id="O2" value="27.259" spread="7.772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.721" spread="23.104"/>
                    <measurement group_id="O2" value="18.662" spread="24.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.978" spread="8.117"/>
                    <measurement group_id="O2" value="18.707" spread="9.175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.263" spread="3.087"/>
                    <measurement group_id="O2" value="13.819" spread="3.381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5495</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2616</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3632</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3393</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (0-inf)</title>
        <description>Steady state systemic exposure parameters</description>
        <time_frame>60 to 30 minutes prior to dosing and over 24 Hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zytiga® (Abiraterone Acetate)</title>
            <description>Zytiga® 1,000 mg (4 x 250 mg qd) tablets</description>
          </group>
          <group group_id="O2">
            <title>SoluMatrix™ (Abiraterone Acetate)</title>
            <description>SoluMatrix™ 500 mg (4 x 125 mg qd) tablets</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-inf)</title>
          <description>Steady state systemic exposure parameters</description>
          <units>ng*hr/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1020.218" spread="154.549"/>
                    <measurement group_id="O2" value="326.458" spread="218.565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (0-24 hr)</title>
        <description>Blood samples for pre-dose PK profiling were to be collected approximately 45 minutes before dosing, i.e., within 60 to 30 minutes prior to dosing. Post-dose blood samples were to be collected throughout the day at the times (15 mins, 30 mins, 1 hr, 1.5 hr, 2.0 hr 3 hr, 4 hr, 6 hr, 8 hr, 9 hr, 24 hr).</description>
        <time_frame>60 to 30 minutes prior to dosing and over 24 Hours post-dose</time_frame>
        <population>Overall, 14 subjects were analyzed in the PK population, amongst which, 8 were in the Zytiga group and 5 were in the SoluMatrix group.</population>
        <group_list>
          <group group_id="O1">
            <title>Zytiga® (Abiraterone Acetate)</title>
            <description>Zytiga® 1,000 mg (4 x 250 mg qd) tablets.</description>
          </group>
          <group group_id="O2">
            <title>SoluMatrix™ (Abiraterone Acetate)</title>
            <description>SoluMatrix™ 500 mg (4 x 125 mg qd) tablets</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-24 hr)</title>
          <description>Blood samples for pre-dose PK profiling were to be collected approximately 45 minutes before dosing, i.e., within 60 to 30 minutes prior to dosing. Post-dose blood samples were to be collected throughout the day at the times (15 mins, 30 mins, 1 hr, 1.5 hr, 2.0 hr 3 hr, 4 hr, 6 hr, 8 hr, 9 hr, 24 hr).</description>
          <population>Overall, 14 subjects were analyzed in the PK population, amongst which, 8 were in the Zytiga group and 5 were in the SoluMatrix group.</population>
          <units>ng*hr/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="870.859" spread="221.709"/>
                    <measurement group_id="O2" value="626.066" spread="280.443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (0-t)</title>
        <description>Blood samples for pre-dose PK profiling were to be collected approximately 45 minutes before dosing, i.e., within 60 to 30 minutes prior to dosing. Post-dose blood samples were to be collected throughout the day at the times (15 mins, 30 mins, 1 hr, 1.5 hr, 2.0 hr 3 hr, 4 hr, 6 hr, 8 hr, 9 hr, 24 hr).</description>
        <time_frame>60 to 30 minutes prior to dosing and over 24 Hours post-dose</time_frame>
        <population>Overall, 14 subjects were analyzed in the PK population, amongst which, 8 were in the Zytiga group and 5 were in the SoluMatrix group.</population>
        <group_list>
          <group group_id="O1">
            <title>Zytiga® (Abiraterone Acetate)</title>
            <description>Zytiga® 1,000 mg (4 x 250 mg qd) tablets</description>
          </group>
          <group group_id="O2">
            <title>SoluMatrix™ (Abiraterone Acetate)</title>
            <description>SoluMatrix™ 500 mg (4 x 125 mg qd) tablets</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-t)</title>
          <description>Blood samples for pre-dose PK profiling were to be collected approximately 45 minutes before dosing, i.e., within 60 to 30 minutes prior to dosing. Post-dose blood samples were to be collected throughout the day at the times (15 mins, 30 mins, 1 hr, 1.5 hr, 2.0 hr 3 hr, 4 hr, 6 hr, 8 hr, 9 hr, 24 hr).</description>
          <population>Overall, 14 subjects were analyzed in the PK population, amongst which, 8 were in the Zytiga group and 5 were in the SoluMatrix group.</population>
          <units>ng*hr/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="870.859" spread="221.709"/>
                    <measurement group_id="O2" value="626.066" spread="280.443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax</title>
        <description>Blood samples for pre-dose PK profiling were to be collected approximately 45 minutes before dosing, i.e., within 60 to 30 minutes prior to dosing. Post-dose blood samples were to be collected throughout the day at the times (15 mins, 30 mins, 1 hr, 1.5 hr, 2.0 hr 3 hr, 4 hr, 6 hr, 8 hr, 9 hr, 24 hr).</description>
        <time_frame>60 to 30 minutes prior to dosing and over 24 Hours post-dose</time_frame>
        <population>Overall, 14 subjects were analyzed in the PK population, amongst which, 8 were in the Zytiga group and 5 were in the SoluMatrix group.</population>
        <group_list>
          <group group_id="O1">
            <title>Zytiga® (Abiraterone Acetate)</title>
            <description>Zytiga® 1,000 mg (4 x 250 mg qd) tablets</description>
          </group>
          <group group_id="O2">
            <title>SoluMatrix™ (Abiraterone Acetate)</title>
            <description>500 mg (4 x 125 mg qd)&#xD;
SoluMatrix™ (Abiraterone Acetate): SoluMatrix™ Abiraterone Acetate 500 mg Compared to Zytiga® 1,000 mg (4 x 250 mg qd)</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Blood samples for pre-dose PK profiling were to be collected approximately 45 minutes before dosing, i.e., within 60 to 30 minutes prior to dosing. Post-dose blood samples were to be collected throughout the day at the times (15 mins, 30 mins, 1 hr, 1.5 hr, 2.0 hr 3 hr, 4 hr, 6 hr, 8 hr, 9 hr, 24 hr).</description>
          <population>Overall, 14 subjects were analyzed in the PK population, amongst which, 8 were in the Zytiga group and 5 were in the SoluMatrix group.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268.261" spread="69.967"/>
                    <measurement group_id="O2" value="111.316" spread="88.503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1917</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected from the time of signing of the ICF until study completion (84 Days). The AEs collected in the source documents for screening failures did not need to be entered into eCRF, however once a potential patient was randomized, all AEs were to be entered into the eCRF.</time_frame>
      <desc>The investigator monitored and/or asked about or evaluated AEs using non-leading questions at each visit or evaluation.</desc>
      <group_list>
        <group group_id="E1">
          <title>Zytiga® (Abiraterone Acetate)</title>
          <description>1,000 MG (4 x 250 mg qd)&#xD;
Zytiga® (Abiraterone Acetate): Zytiga® 1,000 mg (4 x 250 mg qd) Compared to SoluMatrix™ Abiraterone Acetate 500 mg</description>
        </group>
        <group group_id="E2">
          <title>SoluMatrix™ (Abiraterone Acetate)</title>
          <description>500 mg (4 x 125 mg qd)&#xD;
SoluMatrix™ (Abiraterone Acetate): SoluMatrix™ Abiraterone Acetate 500 mg Compared to Zytiga® 1,000 mg (4 x 250 mg qd)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Corornary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Progression of prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of left hydroureteronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastroesophgeal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infections</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatiineincreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head, Clinical Development</name_or_title>
      <organization>SPARC</organization>
      <phone>912266455645</phone>
      <email>clinical.trials@sparcmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

